Research & Development
Prostate Cancer: Page 2
Active surveillance on the rise for low-risk prostate cancer
A large study indicates that active surveillance rates for management of low-risk prostate cancer are rising nationally, but are still not optimal.
March 2, 2023
Bio-Techne's prostate test granted expanded Medicare coverage
The updated Medicare policy covers an annual ExoDx Prostate Test for men who have already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy.
February 24, 2023
Cleveland Diagnostics, Quest Diagnostics expand access to blood-based prostate cancer test
When physicians order the IsoPSA prostate cancer test, their patients will provide blood specimens at a Quest patient service center. Quest will transport the blood samples for testing at a Cleveland Diagnostics’ laboratory.
February 13, 2023
Oxford BioDynamics announces study results for prostate screening blood test
The published results from the multidisciplinary PROSTAGRAM study show that the PSE test had a 92% positive and 94% negative predictive value and an accuracy of 94%.
February 7, 2023
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
Cedars-Sinai Cancer researchers are developing a microfluidic device with a nanosurface as part of a blood test to inform treatment decisions.
February 3, 2023
Avenda Health gets FDA 510(k) clearance for iQuest prostate cancer platform
The iQuest platform provides physicians with a 3D visualization, enabling treatment decisions that consider the extent of the cancer rather than treating the whole organ.
December 8, 2022
MDxHealth sees Medicare delay for prostate cancer risk test, reduces 2022 revenue guide
To obtain Medicare payments for the test, the firm had to submit a Technical Assessment for review and consideration under a Local Coverage Decision (LCD) process recently implemented by the Molecular Diagnostics Services (MolDX) Program.
November 30, 2022
Low-value prostate cancer screening has Medicare spending ramifications, study finds
The consequences of low-value PSA cancer screening could amount to more than $275 million in spending for Medicare, according to the authors' estimates.
November 22, 2022
Higher PSA screening rates associated with less metastatic prostate cancer
Investigators undertook a retrospective cohort study of patients to determine whether facility-level variations in PSA screening rates could be associated with subsequent facility-level metastatic prostate cancer incidence.
October 25, 2022
Veracyte announces data for prostate genomic classifier
September 21, 2022
Veracyte announces data at ESMO 2022 for prostate genomic classifier
The data from a study presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris came from a Phase 3 trial of the multicenter, multinational, randomized STAMPEDE platform protocol. The protocol involves more than 10,000 men to date with high-risk, nonmetastatic or metastatic prostate cancer who are starting long-term androgen-deprivation therapy for the first time and are randomized to new treatments in seven Phase 3 trials.
September 11, 2022
Veracyte to present abstracts at ESMO Congress 2022
The following abstracts will be shared at the event in Paris on September 11:
August 30, 2022
Page 2 of 7